These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36288512)

  • 1. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic
    Brastianos PK; Twohy EL; Gerstner ER; Kaufmann TJ; Iafrate AJ; Lennerz J; Jeyapalan S; Piccioni DE; Monga V; Fadul CE; Schiff D; Taylor JW; Chowdhary SA; Bettegowda C; Ansstas G; De La Fuente M; Anderson MD; Shonka N; Damek D; Carrillo J; Kunschner-Ronan LJ; Chaudhary R; Jaeckle KA; Senecal FM; Kaley T; Morrison T; Thomas AA; Welch MR; Iwamoto F; Cachia D; Cohen AL; Vora S; Knopp M; Dunn IF; Kumthekar P; Sarkaria J; Geyer S; Carrero XW; Martinez-Lage M; Cahill DP; Brown PD; Giannini C; Santagata S; Barker FG; Galanis E
    J Clin Oncol; 2023 Jan; 41(3):618-628. PubMed ID: 36288512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
    Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
    Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
    Soria JC; Gan HK; Blagden SP; Plummer R; Arkenau HT; Ranson M; Evans TR; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Dean E; Brown J; Gibson D; Peddareddigari V; Murray S; Nebot N; Mazumdar J; Swartz L; Auger KR; Fleming RA; Singh R; Millward M
    Ann Oncol; 2016 Dec; 27(12):2268-2274. PubMed ID: 27733373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative treatments for meningiomas.
    Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
    Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
    Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
    Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of frequent NF2 mutations with spinal location predominance and worse outcomes in psammomatous meningiomas.
    Ren L; Xie Q; Deng J; Chen J; Yu J; Wang D; Wakimoto H; Gong Y; Hua L
    J Neurosurg; 2024 Sep; 141(3):593-601. PubMed ID: 38552238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.
    Vasan V; Dullea JT; Devarajan A; Ali M; Rutland JW; Gill CM; Kinoshita Y; McBride RB; Gliedman P; Bederson J; Donovan M; Sebra R; Umphlett M; Shrivastava RK
    J Neurooncol; 2023 Jan; 161(2):309-316. PubMed ID: 36436149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
    Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
    Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
    Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
    Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index.
    Teranishi Y; Okano A; Miyawaki S; Ohara K; Ishigami D; Hongo H; Dofuku S; Takami H; Mitsui J; Ikemura M; Komura D; Katoh H; Ushiku T; Ishikawa S; Shin M; Nakatomi H; Saito N
    Acta Neuropathol Commun; 2022 May; 10(1):76. PubMed ID: 35570314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study.
    Buccoliero AM; Castiglione F; R Degl'Innocenti D; Gheri CF; Garbini F; Taddei A; Ammannati F; Mennonna P; Taddei GL
    Neuropathology; 2007 Feb; 27(1):36-42. PubMed ID: 17319281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
    Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
    Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression.
    Cain SA; Pope B; Mangiola S; Mantamadiotis T; Drummond KJ
    BMC Cancer; 2023 Mar; 23(1):216. PubMed ID: 36882706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy and targeted therapies for meningiomas: what is the evidence?
    Graillon T; Tabouret E; Chinot O
    Curr Opin Neurol; 2021 Dec; 34(6):857-867. PubMed ID: 34629433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crispr/Cas-based modeling of NF2 loss in meningioma cells.
    Waldt N; Kesseler C; Fala P; John P; Kirches E; Angenstein F; Mawrin C
    J Neurosci Methods; 2021 May; 356():109141. PubMed ID: 33753124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF2 mutations in secretory and other rare variants of meningiomas.
    Hartmann C; Sieberns J; Gehlhaar C; Simon M; Paulus W; von Deimling A
    Brain Pathol; 2006 Jan; 16(1):15-9. PubMed ID: 16612978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas.
    Hrachova M; Nguyen ENT; Fu BD; Dandekar MJ; Kong XT; Cadena G; Hsu FPK; Billimek J; Taylor TH; Bota DA
    Front Neurol; 2020; 11():373. PubMed ID: 32435228
    [No Abstract]   [Full Text] [Related]  

  • 20. A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.
    Brown NF; Williams M; Arkenau HT; Fleming RA; Tolson J; Yan L; Zhang J; Singh R; Auger KR; Lenox L; Cox D; Lewis Y; Plisson C; Searle G; Saleem A; Blagden S; Mulholland P
    Neuro Oncol; 2018 Nov; 20(12):1634-1642. PubMed ID: 29788497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.